MAYO CLINIC

Telo Genomics Corp. presented TeloViewSMM's superior performance over the 20-2-20 score in identifying high and low-risk smoldering multiple myeloma (SMM) patients at the IMS 2024 annual meeting. The test, analyzed on a 160-patient cohort, offers high sensitivity and specificity for SMM stratification, addressing a critical unmet need. Dr. Shaji Kumar presented the results, highlighting TeloViewSMM's potential for non-invasive, periodic use via blood tests, with an estimated market of over 500,000 tests per year.

Four farm workers in Washington are presumed to have contracted bird flu from culling infected poultry, marking the state's first human H5N1 cases. The workers experienced mild symptoms and are being treated with antiviral medication. This raises concerns about potential human-to-human transmission, as similar cases have been reported in California and Missouri, where health care workers developed mild respiratory symptoms after exposure to a bird flu patient.

A pilot study by Mayo Clinic and Cedars-Sinai Health System found VR effectively reduced functional dyspepsia symptoms, with potential for broader DGBI treatment.

Nucleus RadioPharma announces new 53,000-square-foot manufacturing facility in Mesa, AZ, set to open in mid-2026, addressing the shortage of high-quality development and manufacturing space for theranostic products. The facility will create 50 new skilled jobs and enhance patient access to life-saving treatments, expediting clinical trials by up to 30%.

Collagenase clostridium histolyticum (CCH) showed safety and efficacy in treating Peyronie disease with ventral curvature, with 68.8% of patients experiencing at least a 30% improvement. No serious adverse events were reported.

A 14-day montelukast course showed no symptom duration reduction in mild/moderate COVID-19, per ACTIV-6 trial. Median symptom resolution was 10 days for both montelukast and placebo groups, with no significant difference in recovery time or adverse events.

Spinogenix, a small molecule drug discovery company, is testing SPG302 in ALS, Alzheimer’s, and schizophrenia, and SPG601 in Fragile X syndrome. Founded by Stella Sarraf, the company focuses on synaptic regeneration using its TAG platform. Spinogenix aims to leverage objective biomarkers and has expanded its program to include glaucoma. The company benefits from collaborations and grants, with Phase 2 trials ongoing.

FDA approves AbbVie's Vyalev for late-stage Parkinson's, a 24-hour infusion improving motor fluctuations over oral drugs, with mild to moderate side effects.

OPTAC-X and Mayo Clinic used satellite-enabled telehealth to guide a successful cardiac arrest resuscitation outside a hospital, highlighting the potential of remote patient monitoring. The technology, detailed in 'Mayo Clinic Proceedings: Digital Health,' combines LTE and satellite communication, a head-mounted camera, and AI for real-time data and predictive insights, aiming to extend medical expertise to remote areas and improve emergency response.

The A4M October Symposium, held at Encore Boston from October 24-26, 2024, features expert-led sessions on functional anti-aging medicine, including certifications in weight management, pellet therapy, IV therapy, gastroenterology, and peptide therapy. The event aims to equip practitioners with actionable skills and insights, addressing current trends and challenges in these fields.